Analysts Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Target Price at $54.33

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have earned an average rating of “Buy” from the nine analysts that are currently covering the company, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $54.33.

Several research analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. TD Cowen initiated coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating on the stock. Guggenheim reaffirmed a “buy” rating and set a $84.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th.

Dianthus Therapeutics Trading Up 12.9 %

Shares of DNTH opened at $17.61 on Friday. Dianthus Therapeutics has a twelve month low of $13.37 and a twelve month high of $32.27. The firm has a market capitalization of $565.72 million, a P/E ratio of -7.04 and a beta of 1.62. The firm’s 50-day moving average is $20.67 and its two-hundred day moving average is $23.38.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The firm had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.40 million. Analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of hedge funds have recently bought and sold shares of DNTH. R Squared Ltd bought a new position in Dianthus Therapeutics in the fourth quarter worth about $26,000. KLP Kapitalforvaltning AS bought a new stake in Dianthus Therapeutics during the fourth quarter worth approximately $33,000. KBC Group NV acquired a new stake in shares of Dianthus Therapeutics in the fourth quarter valued at $35,000. BNP Paribas Financial Markets bought a new position in shares of Dianthus Therapeutics during the 4th quarter valued at about $59,000. Finally, GAMMA Investing LLC grew its position in Dianthus Therapeutics by 3,030.6% in the first quarter. GAMMA Investing LLC now owns 3,882 shares of the company’s stock worth $70,000 after buying an additional 3,758 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.